Sandoz the global leader in generic and biosimilar medicines, today announced the launch of generic rivaroxaban in Germany, in new generic strengths of 10 mg, 15 mg and 20 mg. Rivaroxaban - 1 A Pharma® offers patients in Germany a high-quality, affordable alternative to reference product Xarelto®*, with a list price advantage across all three strengths.
Following successful litigation in Germany, where Sandoz was the first company to challenge the relevant dosage patent3, this launch marks a significant step in expanding access to high-quality, affordable anticoagulant therapies. Sandoz aims to introduce rivaroxaban in additional markets, supporting its Purpose of pioneering access for patients.
Thomas Weigold, Country President Germany, said: “After a 16-month delay, we can finally offer patients access to rivaroxaban in additional strengths. We are very pleased that we have successfully challenged the patent, because every day lost cost patients and the healthcare system in Germany unnecessary money.”
Rivaroxaban - 1 A Pharma® in the 2.5 mg strength was launched in Germany in April 2024, when the main patent expired. Since then, Bayer had been able to continue selling rivaroxaban in the higher and more popular strengths of 10 mg, 15 mg and 20 mg at monopoly prices, protected by preliminary injunctions based on the dosage patent, which was revoked on July 29, 2025.
The launch of these additional strengths marks a major milestone for Sandoz in Germany, where the company now offers the most comprehensive range of rivaroxaban film-coated tablets on the statutory health insurance market1. With this launch, Sandoz joins all open-house discount agreements for rivaroxaban in Germany, further supporting affordability and access for patients and payers.
Rivaroxaban - 1 A Pharma® is an antithrombotic agent4. It is used in adults for stroke prevention in non-valvular atrial fibrillation (15 mg and 20 mg strengths), treatment of deep vein thrombosis and pulmonary embolism, and prevention of recurrence. The 10 mg strength is also indicated for prevention of venous thromboembolism in adults after elective hip or knee replacement surgery. In children and adolescents, the 15 mg and 20 mg strengths are used to treat venous thromboembolism and prevent its recurrence.
